COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #151
Source   PDF   Share   Tweet
See all 181 studies
10/21
Inconc.
Late treatment study
Dubee et al., medRxiv, doi:10.1101/2020.10.19.20214940 (Preprint)
A placebo-controlled double blind trial of hydroxych loroquine in mild-to-moderate COVID-19
Small early terminated late stage (60% on oxygen) RCT in France showing 46% lower mortality.
mortality at 28 days relative risk RR 0.54 [0.21-1.42]
combined mortality/intubation at 28 days relative risk RR 0.74 [0.33-1.70]
If not stopped early and the same trend continued, statistical significance would be reached on 28 day mortality after ~550 patients (1,300 patients were planned).
Mortality results are not provided for subgroups. For the subgroups receiving AZ:
HC Q+(AZ from day 0): combined mortailty/intubation RR 0.16, p = 0.21
(0/10 HC Q+AZ and 3/11 placebo, 0.5 added for calculations due to 0)
HC Q+(AZ later), combined mortality/intubation RR 0.42 [0.05-3.54]
No safety concerns were identified. This study has been presented as negative, however the results do not support that conclusion.
NCT04325893
death, ↓46.0%, p=0.21, mortality at day 28
combined intubation/death, ↓26.0%, p=0.82, combined mortality/intubation at day 28
death, ↓84.4%, p=0.21, HCQ+AZ from day 0 subgroup combined mortality/intubation
(adjusted for zero)
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit